Home Market News <!DOCTYPE html> <html> <head></head> <body> Disappointment Strikes as Cytosorbents Misses the Mark in Vital Trial

Disappointment Strikes as Cytosorbents Misses the Mark in Vital Trial

0
<!DOCTYPE html>
<html>
<head></head>
<body>
  Disappointment Strikes as Cytosorbents Misses the Mark in Vital Trial
Red arrow And dollar finance decline graph- Stock image

Baris-Ozer

Do you ever feel like you’re so close to winning, only to have victory snatched away at the last minute? That’s how it must feel for shareholders of Cytosorbents (NASDAQ:CTSO) right now. The news of the medical device maker’s investigational blood purification system, DrugSorb-ATR, falling short in a pivotal trial caused the stock to tumble by approximately 31% in pre-market trading on Thursday.

It’s not all doom and gloom, though. Apparently, the trial, which was supposed to assess DrugSorb-ATR’s ability to reduce perioperative bleeding in patients on blood thinners, did show promise in a specific subset of patients. Can you believe that? A glimmer of hope in the midst of disappointment!

Who exactly are these special patients, you ask? Well, turns out they were the ones undergoing coronary artery bypass graft (CABG) – making up more than 90% of the study participants, according to Cytosorbents (CTSO). It’s like finding a diamond in the rough.

So, what went wrong? The double-blind and randomized STAR-T trial, conducted in the U.S. and Canada, had 140 patients on AstraZeneca’s (AZN) antithrombotic therapy, ticagrelor (Brilinta), who were prepping for cardiothoracic surgeries. The anticipation was high, but alas, the trial didn’t quite hit the bullseye for the overall group undergoing multiple cardiac surgeries.

But wait, there’s a silver lining! Cytosorbents (CTSO) is geared up to undertake a full data analysis in the next few weeks and, pending the final analysis, hopes that the STAR-T data will provide enough support for regulatory submissions for DrugSorb-ATR in the U.S. and Canada. A comeback story in the making, perhaps?